In this study, we investigated the inhibitory properties of TCM (C1) and TTM (C2 and C3) in two types of PLC, HCC and CCA, in vitro. Standard chemotherapeutics which are currently used in the clinic (sorafenib for HCC and gemcitabine for CCA) were used as positive controls. This evidence concerns the gene HSPG2 and hepatocellular carcinoma.